Quick urine tests may boost opiate addiction treatment success
NCT ID NCT02345655
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether giving doctors a simple urine drug test in their office helps people stay on buprenorphine treatment for opiate addiction. About 42 patients starting buprenorphine with their family doctor took part. The goal was to see if these tests improve treatment retention after six months compared to usual care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
42 people
The number who actually took part.
- Started
-
Apr 2016
- Finished
-
Dec 2020
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
INCLUSION CRITERIA * For GPs:Professional criteria: to practice as a GP, to be in activity, to practice in general ambulatory practice (in a medical office), to regularly manage patients treated with buprenorphine, to be registered in sector 1, consent for participating to the study * For patients: Aged 18 years-old or more, to consult for starting buprenorphine or OMT: * any patient previously treated by buprenorphine or buprenorphine-naloxone but with his/her treatment interrupted for at least 2 months will be considered as a candidate for a new treatment with buprenorphine or buprenorphine-naloxone * any patient previously exposed to opiate maintenance drug obtained illegally "in the street" will not be as treated affiliated to a health insurance scheme, not opposed to participate EXCLUSION CRITERIA \- For patients: to consult for continuing buprenorphine or for another complain related, to opiate substitution treatment, to be known and yet managed by the GP for an opiate substitutive treatment, to have started buprenorphine in a specialized centre or in a hospital, to be treated with methadone, to be treated with methadone and asking a switch toward buprenorphine
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Opiate addiction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clermont-Ferrand Hospital
Clermont-Ferrand, France
-
Grenoble Lyon Hospital
Grenoble, France
-
Marseille Hospital
Marseille, France
-
Nancy Hospital
Nancy, France
-
Service de Pharmacologie Médicale et Clinique - Centre d'addictovigilance - CHU de Toulouse
Toulouse, 31059, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.